Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Lille – page 52

1 340 clinical trials in Lille, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lille at a glance
1 340
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 340 trials in Lille

Open in trial search

Non-small cell lung cancer stage III

Not yet recruiting

Durvalumab personalized consolidation immunotherapy after chemoradiotherapy in patients with stage III non‑small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Pulmonary hypertension

Not yet recruiting

Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Colitis ulcerative

Not yet recruiting

Safety and efficacy of stopping versus maintenance dose of filgotinib, tofacitinib and upadacitinib in adult ulcerative colitis patients in deep remission

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Centre Hospitalier Regional De Marseille

Pancreatic neuroendocrine tumour

Not yet recruiting

Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Institut Gustave Roussy

Cystic fibrosis

Not yet recruiting

Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Vertex Pharmaceuticals Inc.

T-cell type acute leukaemia

Not yet recruiting

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier De Versailles

Neoplasm malignant+1

Not yet recruiting

Phase I/II study of DJI136 with drug combination in adult patients with extensive-stage small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Osteomyelitis

Not yet recruiting

Zoledronic acid versus placebo for pain relief in children with chronic recurrent multifocal osteomyelitis resistant to NSAIDs

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Zoledronic Acid
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer

Not yet recruiting

Morning Versus Afternoon Pembrolizumab, Carboplatin, and Pemetrexed in Adults With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic scleroderma

Not yet recruiting

Rituximab versus placebo for maintenance therapy in adults with stabilized systemic sclerosis‑associated interstitial lung disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Assistance Publique Hopitaux De Paris

Neoplasm+2

Not yet recruiting

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Embolism

Not yet recruiting

A study to evaluate the effectiveness of REGN7508 for preventing blood clots in adults with solid tumors undergoing cancer treatment.

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Lille

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma, exploring novel treatment combinations and targeted therapies. Additional research includes investigations into pancreatic cancer and gastric cancer treatments.

  • Advanced cancer therapies
  • Targeted molecular treatments
  • Combination therapy approaches

Studies are evaluating innovative therapeutic agents and their effectiveness in treating various forms of cancer.

02 Neurological Disorders

Comprehensive research into Alzheimer's disease and Amyotrophic Lateral Sclerosis, examining new treatment approaches and disease mechanisms. Studies also include investigations of essential tremor treatments.

  • Neurodegenerative diseases
  • Movement disorders
  • Brain imaging studies

Research focuses on understanding disease progression and developing targeted interventions.

03 Autoimmune and Inflammatory Conditions

Innovative trials examining treatments for Crohn's disease and Multiple Sclerosis. Research includes novel approaches to managing chronic inflammatory conditions and immune system disorders.

  • Inflammatory bowel diseases
  • Immunotherapy approaches
  • Disease modification strategies

Studies aim to improve treatment outcomes and develop more effective therapeutic options.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.